HUNTINGTON, W.Va., Dec. 1, 2025 /PRNewswire/ -- Cornerstone Community Development, in cooperation with Winterwood, CVS Health® (NYSE: CVS) and other community organizations, invites the public and media to a special event celebrating the transformation of one of Huntington's most historic properties. The Prichard Centennial Residential Reveal & Next-Phase Preview will be held on Thursday, December 4, 2025, at 1:30 p.m. at 601 9th Street, Huntington, WV 25701.
This milestone event will highlight the newly completed residential spaces inside the Prichard building and showcase the next phase of the project—an ongoing effort to restore the landmark while expanding housing opportunities, improving community wellbeing, and supporting downtown revitalization.
"The Prichard has long been a pillar of Huntington's identity," said Nikki Thomas, President at Cornerstone Community Development. "This moment reflects a shared commitment to preserving history, strengthening our neighborhoods, and creating new opportunities."
CVS Health and additional organizations have played an important role in supporting the development's community-focused goals. Recognizing the connection of housing to health, CVS Health has invested more than $17 million towards the adaptive-reuse and rehabilitation of the Prichard into affordable senior housing. The company's investment in the Prichard builds on CVS Health and Aetna's long history of community support in West Virginia. In addition to their investment in the Prichard, CVS Health has invested over $21 million in affordable housing across the state, helping to create or preserve over 800 affordable units.
"Housing is more than a roof over someone's head. It's peace of mind, dignity, and a foundation for wellbeing," said Don Mazza, Chief Medicare Officer, Keystone Market, Aetna, a CVS Health company. "The transformation of the Prichard serves as a powerful example of what can be achieved through community-focused collaboration. Through our investment and collaboration with Winterwood and Cornerstone Community Development, we're helping to ensure Huntington's seniors have a safe, welcoming place to call home."
Mike Hynes, Chief Executive Officer at Winterwood noted, "Revitalizing the Prichard is a collaborative effort. Together with our partners, we are bringing renewed energy and purpose to this iconic building."
The event is free and open to the public, and media outlets are encouraged to attend for coverage, interviews, and visual opportunities.
For questions or more information, please contact (304) 939-5726.
About CVS Health
CVS Health is a leading health solutions company building a world of health around every consumer, wherever they are. As of September 30, 2025, the Company had approximately 9,000 retail pharmacy locations, more than 1,000 walk-in and primary care medical clinics and a leading pharmacy benefits manager with approximately 87 million plan members. The Company also serves an estimated more than 37 million people through traditional, voluntary and consumer-directed health insurance products and related services, including highly rated Medicare Advantage offerings and a leading standalone Medicare Part D prescription drug plan. The Company's integrated model uses personalized, technology driven services to connect people to simply better health, increasing access to quality care, delivering better outcomes, and lowering overall costs.
Media contact
Rebecca Ferrick
This email address is being protected from spambots. You need JavaScript enabled to view it.

| Last Trade: | US$79.10 |
| Daily Change: | -1.26 -1.57 |
| Daily Volume: | 5,896,577 |
| Market Cap: | US$100.460B |
November 20, 2025 November 18, 2025 October 15, 2025 | |

Terns Pharmaceuticals is a clinical-stage biopharmaceutical company developing a portfolio of small-molecule product candidates to address serious diseases, including oncology and obesity. Terns’ pipeline contains three clinical stage development programs including GLP-1 receptor...
CLICK TO LEARN MORE
Compass Therapeutics is a clinical-stage, oncology-focused biopharmaceutical company developing proprietary antibody-based therapeutics to treat multiple human diseases. The company's scientific focus is on the relationship between angiogenesis, the immune system, and tumor growth...
CLICK TO LEARN MOREEnd of content
No more pages to load